Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (610) Arrow Down
Filter Results: (610) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (610)
    • People  (4)
    • News  (110)
    • Research  (426)
    • Events  (3)
    • Multimedia  (4)
  • Faculty Publications  (259)

Show Results For

  • All HBS Web  (610)
    • People  (4)
    • News  (110)
    • Research  (426)
    • Events  (3)
    • Multimedia  (4)
  • Faculty Publications  (259)
← Page 9 of 610 Results →
  • 11 Apr 2019
  • News

The DNA of Sustained Innovation

  • March 2008
  • Case

Novartis AG: Science-Based Business

By: H. Kent Bowen and Courtney Purrington
Novartis is a science-based drug company, which has important implications for its business strategy. It is one of the largest pharmaceutical companies in the world with over $38B in sales in 2007. Pharmaceuticals account for slightly over $24B of that total. In 2007,... View Details
Keywords: Innovation and Invention; Resource Allocation; Product Development; Partners and Partnerships; Research and Development; Science-Based Business; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Bowen, H. Kent, and Courtney Purrington. "Novartis AG: Science-Based Business." Harvard Business School Case 608-136, March 2008.
  • August 2011 (Revised October 2011)
  • Case

PureTech Ventures in 2011

By: Andrei Hagiu, Cesar Castro and Sarah Murphy
In early May 2011, Daphne Zohar, founder and managing partner of PureTech Ventures, a life science venture creation company in Boston, MA, was reviewing a term sheet she had just received from a venture capital (VC) firm for one of PureTech's portfolio companies. The... View Details
Keywords: Business Ventures; Business Startups; Venture Capital; Investment; Innovation and Invention; Negotiation; Partners and Partnerships; Science-Based Business; Opportunities; Boston
Citation
Educators
Purchase
Related
Hagiu, Andrei, Cesar Castro, and Sarah Murphy. "PureTech Ventures in 2011." Harvard Business School Case 712-419, August 2011. (Revised October 2011.)
  • 11 May 2012
  • Working Paper Summaries

Creating an R&D Strategy

Keywords: by Gary P. Pisano
  • September 2007 (Revised December 2008)
  • Case

Michael Fernandes at Nicholas Piramal

By: Michel Anteby and Nitin Nohria
Michael Fernandes, the Director of Custom Manufacturing Operations at the pharmaceutical company Nicholas Piramal India Limited (NPIL), schedules a meeting with three of his reports, whose interpersonal conflicts with one another are causing his business development... View Details
Keywords: Interpersonal Communication; Management Skills; Groups and Teams; Conflict Management; Cooperation; Pharmaceutical Industry; India; United Kingdom; Canada
Citation
Educators
Purchase
Related
Anteby, Michel, and Nitin Nohria. "Michael Fernandes at Nicholas Piramal." Harvard Business School Case 408-001, September 2007. (Revised December 2008.)
  • March 2008 (Revised July 2011)
  • Supplement

Cadbury Schweppes: Capturing Confectionery (D)

By: David Collis, Toby Stuart and Troy Smith
In late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a... View Details
Keywords: Food; Mergers and Acquisitions; Corporate Strategy
Citation
Purchase
Related
Collis, David, Toby Stuart, and Troy Smith. "Cadbury Schweppes: Capturing Confectionery (D)." Harvard Business School Supplement 708-491, March 2008. (Revised July 2011.)
  • March 2008 (Revised January 2023)
  • Supplement

Cadbury Schweppes: Capturing Confectionery (B)

By: David Collis, Toby Stuart and Troy Smith
In late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a... View Details
Keywords: Food; Mergers and Acquisitions; Corporate Strategy; Food and Beverage Industry
Citation
Purchase
Related
Collis, David, Toby Stuart, and Troy Smith. "Cadbury Schweppes: Capturing Confectionery (B)." Harvard Business School Supplement 708-454, March 2008. (Revised January 2023.)
  • September 2023 (Revised December 2023)
  • Case

TetraScience: Noise and Signal

By: Thomas R. Eisenmann and Tom Quinn
In 2019, TetraScience CEO “Spin” Wang needed advice. Five years earlier, he had cofounded a startup that saw early success with a hardware product designed to help laboratory scientists in the biotechnology and pharmaceutical spaces more easily collect data from... View Details
Keywords: Entrepreneurship; Business Growth and Maturation; Business Organization; Restructuring; Forecasting and Prediction; Digital Platforms; Analytics and Data Science; AI and Machine Learning; Organizational Structure; Network Effects; Competitive Strategy; Pharmaceutical Industry; Pharmaceutical Industry; United States; Boston
Citation
Educators
Purchase
Related
Eisenmann, Thomas R., and Tom Quinn. "TetraScience: Noise and Signal." Harvard Business School Case 824-024, September 2023. (Revised December 2023.)
  • September 2014
  • Case

Pfizer's Centers for Therapeutic Innovation (CTI)

By: Gary Pisano, James Weber and Kait Szydlowski
In 2010, Pfizer established four small research units in New York, Boston, San Francisco, and San Diego located close to several premier Academic Medical Centers (AMCs), or hospitals with adjoining medical schools. The goal of these units was to redesign collaboration... View Details
Keywords: Drug Development; Academic Collaboration; Research And Development; Innovation; Translational Research; Management; Operations; Problems and Challenges; Research; Science; Information Technology; Strategy; Pharmaceutical Industry; Pharmaceutical Industry; North and Central America; Europe; Asia
Citation
Educators
Purchase
Related
Pisano, Gary, James Weber, and Kait Szydlowski. "Pfizer's Centers for Therapeutic Innovation (CTI)." Harvard Business School Case 615-024, September 2014.

    Leemore S. Dafny

    Leemore Dafny is the Bruce V. Rauner Professor of Business Administration and the Howard Cox Health Care Initiative Faculty Co-Chair at the Harvard Business School. She also serves as Professor of Public Policy at the Harvard Kennedy School. Dafny is an... View Details

    Keywords: health care
    • March 2011 (Revised February 2012)
    • Case

    Innovation and Growth at Actelion Ltd.

    By: Gary P. Pisano, Daniela Beyersdorfer and Ruth Dittrich
    In late 2010, Jean-Paul Clozel, CEO of the Swiss biotech pharmaceuticals firm Actelion, looks back on a successful decade. The small venture that he had started with a few of his scientist colleagues in the late 1990s to discover novel medicine in a research-driven... View Details
    Keywords: Business Model; Talent and Talent Management; Innovation and Management; Leadership; Growth and Development Strategy; Product Development; Organizational Culture; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland
    Citation
    Educators
    Purchase
    Related
    Pisano, Gary P., Daniela Beyersdorfer, and Ruth Dittrich. "Innovation and Growth at Actelion Ltd." Harvard Business School Case 611-065, March 2011. (Revised February 2012.)
    • 16 May 2023
    • HBS Case

    How KKR Got More by Giving Ownership to the Factory Floor: ‘My Kids Are Going to College!’

    pharmaceuticals and technology. Rouen cautions that the model works best in fast-growing companies, where employees can receive a sizeable payout, and in situations where a sale in the not-too-distant future can translate into wealth.... View Details
    Keywords: by Avery Forman
    • January 2001 (Revised July 2003)
    • Case

    Pharmacyclics: Financing Research & Development

    By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
    Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more... View Details
    Keywords: Valuation; Cash Flow; Financing and Loans; Business Startups; Financial Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
    Citation
    Educators
    Purchase
    Related
    Baker, Malcolm P., Richard S. Ruback, and Aldo Sesia. "Pharmacyclics: Financing Research & Development." Harvard Business School Case 201-056, January 2001. (Revised July 2003.)
    • March 2008 (Revised July 2011)
    • Supplement

    Cadbury Schweppes: Capturing Confectionery (C)

    By: David Collis, Toby Stuart and Troy Smith
    In late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a... View Details
    Keywords: Food; Mergers and Acquisitions; Corporate Strategy; Food and Beverage Industry
    Citation
    Purchase
    Related
    Collis, David, Toby Stuart, and Troy Smith. "Cadbury Schweppes: Capturing Confectionery (C)." Harvard Business School Supplement 708-455, March 2008. (Revised July 2011.)
    • October 2023 (Revised June 2024)
    • Case

    Catalent: Catalyzing the Next Era of Growth

    By: Satish Tadikonda, William Marks and Kevin Emancipator
    Catalent's newly appointed CEO, Alessandro Maselli, experienced the highs of the pharmaceutical contract development manufacturing (CDMO) space during COVID-19 while helping Moderna and others bring vaccines to market quickly and safely. After rushing to add capacity... View Details
    Keywords: Leadership; Business or Company Management; Organizational Change and Adaptation; Pharmaceutical Industry
    Citation
    Educators
    Purchase
    Related
    Tadikonda, Satish, William Marks, and Kevin Emancipator. "Catalent: Catalyzing the Next Era of Growth." Harvard Business School Case 824-016, October 2023. (Revised June 2024.)
    • 12 Feb 2008
    • First Look

    First Look: February 12, 2007

    passions of far-flung workforces stress openness, inclusion, and making the world a better place. Through this shift in what might be called their guidance systems, the companies have become as creative and nimble as much smaller ones,... View Details
    Keywords: Martha Lagace
    • April 2019 (Revised January 2025)
    • Case

    Clear Link Technologies, LLC: Driving Sales with Peer Effects

    By: Christopher Stanton, Richard Saouma and Olivia Hull
    The importance of a good peer or coworker is widely discussed, but understanding the glue that makes coworkers valuable is less understood. This case sheds light on the importance of peers and the practices and environments that make a group greater than the sum of its... View Details
    Keywords: Talent and Talent Management; Interactive Communication; Experience and Expertise; Decision Making; Training; Design; Compensation and Benefits; Knowledge Acquisition; Knowledge Sharing; Human Capital; Working Conditions; Measurement and Metrics; Outcome or Result; Performance; Performance Improvement; Research; Sales; Salesforce Management; Motivation and Incentives; Telecommunications Industry; Utah; United States
    Citation
    Educators
    Purchase
    Related
    Stanton, Christopher, Richard Saouma, and Olivia Hull. "Clear Link Technologies, LLC: Driving Sales with Peer Effects." Harvard Business School Case 819-072, April 2019. (Revised January 2025.)
    • Research Summary

    Regulatory negotiations and risk communication

    In the pharmaceutical industry a drugs benefits and risks are constantly being weighed by companies, regulators, physicians and drug consumers. While companies and regulators must make decisions based on population statistics about drug outcomes, physicians and drug... View Details
    • 02 Feb 2021
    • Blog Post

    Finding My Focus in Health care Amidst a Global Pandemic

    decade, legislators have passed countless health care policies that impact how hospitals, insurance companies and pharmaceutical manufacturers deliver services to patients. Even more, the ongoing SARS-CoV-2... View Details
    • 21 Feb 2018
    • Research & Ideas

    When a Competitor Abandons the Market, Should You Advance or Retreat?

    Terminations: Learning from Competitors’ R&D Failures, Krieger explores how pharmaceutical companies choose to react strategically when a competitor exits the market during the development stage. These... View Details
    Keywords: by Rachel Layne; Pharmaceutical; Pharmaceutical
    • ←
    • 9
    • 10
    • …
    • 30
    • 31
    • →
    ǁ
    Campus Map
    Harvard Business School
    Soldiers Field
    Boston, MA 02163
    →Map & Directions
    →More Contact Information
    • Make a Gift
    • Site Map
    • Jobs
    • Harvard University
    • Trademarks
    • Policies
    • Accessibility
    • Digital Accessibility
    Copyright © President & Fellows of Harvard College.